Jaysen S. Chung

Jaysen Chung is a seasoned intellectual property litigator with 13 years of experience and also holds a degree in psychobiology.

"Being an IP lawyer allows me to combine those substantive interests with my passion for advocacy and writing," he said.

As a partner at Gibson Dunn's San Francisco office, Chung's expertise spans across patent and appellate litigation, with a focus on a diverse range of arts and practices including pharmaceuticals, biotechnology, DNA sequencing applications, artificial intelligence, virtual networking and base station technology.

Chung's commitment to the legal community extends beyond the courtroom, as evidenced by his service on the board of directors for the Asian American Bar Association and previous role as co-chair of AABA's LGBTQ+ Committee.

A self-proclaimed "Section 101 nerd," Chung has maintained a comprehensive database of all district court and Federal Circuit decisions on the issue since the landmark Alice decision in 2014, showcasing a dedication to the intricacies of patent law.

Notably, in the Archer litigation, Chung leveraged their extensive knowledge and experience with Section 101 issues to contribute to a successful team outcome.

His team scored a victory for Archer Aviation, saving his client from a potentially devastating preliminary injunction. Wisk Aero LLC alleged a conspiracy of misappropriation of trade secrets by Archer relating to its electric vertical takeoff and landing (eVTOL) aircraft.

Similarly, in the WSOU litigation to obtain, he obtained a complete victory at trial.

"The case started in the height of the pandemic in 2020, and there was so much tireless effort and great teamwork that went into the entire litigation," Chung said. "So, nearly three years later when we were back in person and at trial, it was very satisfying to have achieved that precedent-setting result."

Lastly, Chung and a team represented EMD Serono, Inc. and Pfizer Inc.in a long-running patent dispute brought by biotechnology company, Biogen. Nearly 15 years ago, Biogen sued his clients for alleged patent infringement in connection with the marketing and sale of Serono's leading MS medicine, Rebif.

In October 2021, the Supreme Court denied Biogen's petition for a writ of certiorari, ending a dispute in which Biogen sought more than $5.4 billion in damages. The win marks the largest defense victory in a patent infringement suit to date.

"We were a small and close-knit team in a trial that lasted nearly five weeks," Chung said. "I was an associate at the time and was fortunate that our lead counsel, Wayne Barsky, gave me and others opportunities to examine witnesses at trial, argue motions, you name it. This case ran the gamut of issues you will see in any patent case and will stay with me for the rest of my career."